Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005

Vaccine

Volumn 26, Issue 29-30, 2008, Pages 3765-3771

  Harboe, Zitta B ^a   Valentiner Branth, Palle ^a   Benfield, Thomas L ^b   Christensen, Jens Jørgen ^a   Hjuler, Thomas ^a   Kaltoft, Margit ^a   Krogfelt, Karen A ^a   Lambertsen, Lotte ^a   Konradsen, Helle B ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Mortality; Pneumococcal infections; Pneumococcal vaccines

Indexed keywords

ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DENMARK; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 45049085583     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.040     Document Type: Article

References (46)

1. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Weekly Epidemiol Rec 82 12 (2007) 93-104
2. Meyer C.N., Schonheyder H.C., Bangsborg J., Nielsen X.C., Moller J.K., Molbak K., et al. Bacterial meningitis in Denmark 2002-2003. A nation-wide laboratory-based registration. Ugeskr Laeger 169 6 (2007) 503-506
3. Howitz M, Mølback K. Purulent meningtis, 2005 [Bacterial meningitis 2005]. EPI-NEWS 2006; no. 39. Available at: http://www.ssi.dk/sw44292.asp; 2007 [accessed 12.09.07].
4. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
5. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
6. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005) 2043-2051
7. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR 54 (2005) 893-916
8. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007;369(9568):1179-86.
9. Pebody R., Leino T., Nohynek H., Hellenbrand W., Salmaso S., and Ruutu P. Pneumococcal vaccination policy in Europe. Eur Surveill 10 9 (2005)
10. Pneumokokvaccination indføres i det danske børnevaccinationsprogram [Introduction of pneumococcal vaccination in the Danish Childhood immunization programme]. EPI-NEWS 2007; no. 27-33. Available at: http://www.ssi.dk/sw50637.asp; 2007 [accessed 12.09.07].
11. Pebody R.G., Hellenbrand W., D'Ancona F., and Ruutu P. Pneumococcal disease surveillance in Europe. Eur Surveill 11 9 (2006) 171-178
12. Tzanakaki G., and Mastrantonio P. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int J Antimicrob Agents 29 6 (2007) 621-629
13. Kaltoft M., Zeuthen N., and Konradsen H.B. Epidemiology of invasive pneumococcal infections in children aged 0-6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr Suppl 89 435 (2000) 3-10
14. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 33 10 (1995) 2759-2762
15. Sorensen U.B. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol 31 8 (1993) 2097-2100
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Seventeenth informational supplement. CLSI document M100-S17 vol. 27. No. 1; 2007 (ISBN 1-56238-625-5).
17. Pedersen C.B., Gotzsche H., Moller J.O., Mortensen P.B., and The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53 4 (2006) 441-449
18. Andersen T.F., Madsen M., Jorgensen J., Mellemkjoer L., Olsen J.H., and The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46 3 (1999) 263-268
19. Oosterhuis-Kafeja F., Beutels P., and Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25 12 (2007) 2194-2212
20. Andersen PH, Valentiner-Branth P, Glismann S, Simonsen JB. Di-Te-Ki-Pol-Hib vaccination, tilslutning ultimo 2005 [Adherence to the Danish Childhood Immunization Programme, 2005] EPI-NEWS 2007, no. 8. Available at: http://www.ssi.dk/sw48196.asp; 2008 [accessed 14.02.08].
21. Isaacman D.J., Fletcher M.A., Fritzell B., Ciuryla V., and Schranz J. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine 25 13 (2007) 2420-2427
22. Hammitt L.L., Bruden D.L., Butler J.C., Baggett H.C., Hurlburt D.A., Reasonover A., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193 11 (2006) 1487-1494
23. McBean A.M., Jung K., and Hebert P.L. Decreasing invasive pneumococcal disease in the elderly: a state-level analysis. Vaccine 24 27-28 (2006) 5609-5614
24. Sims R.V., Steinmann W.C., McConville J.H., King L.R., Zwick W.C., and Schwartz J.S. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 108 5 (1988) 653-657
25. Shapiro E.D., and Clemens J.D. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 101 3 (1984) 325-330
26. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm.Rep. 1997;46(RR-8):1-24.
27. MMWR Recomm.Rep. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm.Rep. 1997;46(RR-8):1-24.
28. McIntosh E.D., Fritzell B., and Fletcher M.A. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol Infect 135 4 (2007) 644-656
29. Yaro S., Lourd M., Traore Y., Njanpop-Lafourcade B.M., Sawadogo A., Sangare L., et al. Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis 43 6 (2006) 693-700
30. Leimkugel J., Adams F.A., Gagneux S., Pfluger V., Flierl C., Awine E., et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis 192 2 (2005) 192-199
31. Gratten M., Morey F., Dixon J., Manning K., Torzillo P., Matters R., et al. An outbreak of serotype 1 Streptococcus pneumoniae infection in central Australia. Med J Aust 158 5 (1993) 340-342
32. Juven T., Mertsola J., Waris M., Leinonen M., Meurman O., Roivainen M., et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 19 4 (2000) 293-298
33. Vuori-Holopainen E., Salo E., Saxen H., Hedman K., Hyypia T., Lahdenpera R., et al. Etiological diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiological methods. Clin Infect Dis 34 5 (2002) 583-590
34. Hansen J., Black S., Shinefield H., Cherian T., Benson J., Fireman B., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 25 9 (2006) 779-781
35. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 9465 (2005) 1139-1146
36. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive Pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 16 (2007) 1784-1792
37. Pelton S.I., Huot H., Finkelstein J.A., Bishop C.J., Hsu K.K., Kellenberg J., et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 26 6 (2007) 468-472
38. Farrell D.J., Klugman K.P., and Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26 2 (2007) 123-128
39. Meiniche H.K., Lundgren B., Konradsen H.B., and Benfield T.L. Streptococcus pneumoniae meningitis in adults. Hvidovre University Hospital, 1988-2002. Ugeskr Laeger 167 18 (2005) 1961-1964
40. Evers S., Ament A., Colombo G., Konradsen H., Reinert R., Sauerland D., et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 26 8 (2007) 531-540
41. Hennessy T.W., Singleton R.J., Bulkow L.R., Bruden D.L., Hurlburt D.A., Parks D., et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 23 48/49 (2005) 5464-5473
42. Aristegui J., Bernaola E., Pocheville I., García C., Arranz L., Durán G., et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 26 5 (2007) 303-310
43. Riedel S., Beekmann S., Heilmann K., Richter S., Garcia-de-Lomas J., Ferech M., et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 26 7 (2007) 485-490
44. Bruinsma N., Kristinsson K.G., Bronzwaer S., Schrijnemakers P., Degener J., Tiemersma E., et al. Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe. J Antimicrob Chemother 54 6 (2004) 1045-1050
45. Barricarte A., Castilla J., Gil-Setas A., Torroba L., Navarro-Alonso J.A., Irisarri F., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 44 11 (2007) 1436-1441
46. Alanee S.R.J., McGee L., Jackson D., Chiou C.C., Feldman C., Morris A.J., et al. Association of Serotypes of Streptococcus pneumoniae with Disease Severity and Outcome in Adults: An International Study. Clin Infect Dis 45 1 (2007) 46-51